News | April 21, 2009

Tomotherapy Shows Prostate Motion Affects Target Dose Only Slightly

April 21, 2009 – In a study in which researchers from the MD Anderson Cancer Centre Orlando, FL, and the University of Wisconsin, Madison, conducted an analysis of prostate motion during helical tomotherapy, they concluded that the impact on target dose is actually quite small (Int. J. Rad. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2008.09.035).

The study marked the first time that helical tomotherapy has been considered in similar detail. Researchers used electromagnetic markers by Calypso Medical Technologies to track prostate motion. Three markers were implanted under ultrasound guidance in 16 patients who went on to receive IMRT. Tomotherapy treatment plans were generated retrospectively and compared with motion tracks from the markers.

Two separate scenarios were considered. The first assumed that treatment started at the beginning of the observation period. The second anticipated an estimated delay of five minutes between patient alignment and the start of treatment. The minimum dose (Dmin), maximum dose (Dmax) and dose to 95 percent of the volume (D95 percent) were calculated for the whole prostate and for the planning target volume (PTV). These values were then compared with the doses that would have been delivered had the prostate stayed still. The cumulative effect was also evaluated over the course of treatment.

The results showed that for individual fractions, target D95 percent could be reduced by as much as 20 percent. However, the effect of such sizeable dose reductions diminished quickly as treatment continued. The effect on target D95 percent was less than 1 percent by the time that five fractions had been delivered. The biggest surprise was the similarity in observed changes to D95 percent for the prostate and the PTV.

While the results only apply to whole-prostate tomotherapy, researchers will test other techniques that may be affected more by organ motion, such as dose-painting, in a follow-up study.

For more information:

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init